XML 32 R20.htm IDEA: XBRL DOCUMENT v3.25.2
LICENSING AGREEMENTS (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Aug. 31, 2024
Feb. 28, 2022
Dec. 28, 2020
May 17, 2017
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Aug. 31, 2023
Sep. 30, 2021
Jan. 31, 2021
Dec. 31, 2020
Dec. 12, 2020
Feb. 02, 2016
Number of shares                             43,112
Initial payment             $ 100,000                
Payment for clinical trial             200,000                
Common Stock Value         $ 2,586   2,586   $ 1,749           $ 100,000
Total obligation under the agreement         $ 300,000   $ 300,000       $ 300,000 $ 300,000 $ 300,000 $ 100,000  
Common stock, shares, issued         2,585,532   2,585,532   1,748,428            
Initial payment of obligation                     $ 40,000 $ 50,000 $ 50,000 $ 50,000  
Balance of obligation, description             The remaining portion of the $300,000 obligation was paid in cash in 2020                
Remaining portion of obligation         $ 100,000   $ 100,000     $ 100,000          
Amortization expenses         30,742 $ 29,271 61,319 $ 58,542              
Amortization expenses             22,970                
Carrying value of patent         41,524   41,524                
Description of payment on conversion basis       Payment may be made in cash or shares of our common at a discount of 30% to the lowest closing price within 20 business days prior to the conversion date                      
Description for the consecutive trading days       In the event the Company’s shares of common stock trade below $0.01 per share for two or more consecutive trading days, the number of any shares issuable as payment doubles                      
Payments upon completion of the IRB clinical trial       $ 200,000                      
Payments in the event of commercialization of technology       300,000                      
Licensing Agreements [Member]                              
Payments upon dosing of the first patient in Phase 3 clinical trial       100,000                      
Patents [Member]                              
Carrying value of patent         41,524   41,524                
License Agreement [Member]                              
Amortization expenses             586 586              
Carrying value of patent         275   275                
Amortization             $ 275                
ImmCelz Patent [Member]                              
Discount Rate             25.00%                
Amortization expenses             $ 9,912 0              
Interest rate             5.00%                
Royalty percentage rate             5.00%                
Carrying value of patent         185,049   $ 185,049                
Exercise Price             $ 0.0037                
Amortization             $ 20,000                
EDI Patent [Member]                              
Amortization expenses             4,986 4,986              
Carrying value of patent         6,083   6,083                
Amortization             6,083                
IND [Member]                              
Amortization expenses             5,119 4,981              
Carrying value of patent         79,055   79,055                
Amortization             $ 10,000                
Lower Back Patent [Member]                              
Balance of obligation, description             The Company is required to pay CMH $100,000 within 30 days of demand as an initial payment                
CMH [Member]                              
Common Stock, shares                     8,466 8,929   667  
Common stock, shares, issued                         14    
Option Warrant [Member]                              
Initial payment       100,000                      
Amortization expenses             $ 12,479 12,500              
Carrying value of patent         137,521   137,521                
Amortization             25,000                
Payments upon dosing of the first patient in Phase 3 clinical trial       400,000                      
Payments upon dosing of the first patient first patient in a Phase 1-2 clinical trial $ 200,000     $ 200,000                      
Jadi Cell [Member]                              
Pyment For License fees   $ 250,000 $ 250,000                        
Common stock, shares, issued   18,018                          
StemSpine LLC [Member]                              
Amortization expenses             5,267 $ 5,000              
Carrying value of patent         $ 19,733   $ 19,733                
Expiration period of finite-lived intangible assets             May 19, 2027                
Amortization             $ 10,000